The Darkest Hour Is After DAYBREAK For Lundbeck’s New Antipsychotic
The first Phase III study for Lundbeck’s novel antipsychotic flops leaving the Danish company shares down by 25% as investors wonder what’s left in the pipeline.
The first Phase III study for Lundbeck’s novel antipsychotic flops leaving the Danish company shares down by 25% as investors wonder what’s left in the pipeline.